RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma

References

• International Agency for Research on Cancer . Oesophagial fact sheet, 2020. Global Cancer Observatory (2020). https://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-fact-sheet.pdf
   Google Scholar
• Qiu MJ , YangSL, WangMMet al. Prognostic evaluation of esophageal cancer patients with stages I–III. Aging (Albany NY)12(14), 14736–14753 (2020).
   PubMedGoogle Scholar
• Abbas G , KrasnaM. Overview of esophageal cancer. Ann. Cardiothorac. Surg.6(2), 131–136 (2017).
   PubMed Web of Science ®Google Scholar
• Arnold M , SoerjomataramI, FerlayJ, FormanD. Global incidence of oesophageal cancer by histological subtype in 2012. Gut64(3), 381–387 (2015).
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People's Republic of China . Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version). Chin. J. Cancer Res.31(2), 223–258 (2019).
   PubMed Web of Science ®Google Scholar
• Urba SG , OrringerMB, IanettonniM, HaymanJA, SatoruH. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer98(10), 2177–2183 (2003).
   PubMed Web of Science ®Google Scholar
• Ai D , YeJ, ChenYet al. Final results of a Phase III randomized trial of comparison of three paclitaxel-based regimens concurrent with radiotherapy for patients with local advanced esophageal squamous cell carcinoma (ESO-Shanghai2). Rad. Oncol.103(3), ( abstract 91) 4564 (2020).
   Google Scholar
• Stahl M , BudachW. Definitive chemoradiotherapy. J. Thorac. Dis.9(Suppl. 8), S792–S798 (2017).
   PubMedGoogle Scholar
• Barbetta A , HsuM, TanKSet al. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. J. Thorac. Cardiovasc. Surg.155(6), 2710–2721e2713 (2018).
   PubMed Web of Science ®Google Scholar
• Sasaki Y , KatoK. Chemoradiotherapy for esophageal squamous cell cancer. Jpn J. Clin. Oncol.46(9), 805–810 (2016).
   PubMed Web of Science ®Google Scholar
• Conroy T , GalaisMP, RaoulJLet al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, Phase II/III trial. Lancet Oncol.15(3), 305–314 (2014).
   PubMed Web of Science ®Google Scholar
• Cooper JS , GuoMD, HerskovicAet al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA281(17), 1623–1627 (1999).
   PubMed Web of Science ®Google Scholar
• Crosby T , HurtCN, FalkSet al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, Phase II/III randomised trial. Lancet Oncol.14(7), 627–637 (2013).
   PubMed Web of Science ®Google Scholar
• Kelly RJ , AjaniJA, KuzdzaJet al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): first results of the CheckMate 577 study. Ann. Oncol.31(Suppl.4), S1193–S1194 (2020).
   Google Scholar
• Kato K , ChoBC, TakahashiMet al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, Phase III trial. Lancet Oncol.20(11), 1506–1517 (2019).
   PubMed Web of Science ®Google Scholar
• Yamamoto S , KatoK, DaikoHet al. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncol.16(19), 1351–1357 (2020).
   PubMed Web of Science ®Google Scholar
• Kojima T , ShahMA, MuroKet al. Randomized Phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol.38(35), 4138–4148 (2020).
   PubMed Web of Science ®Google Scholar
• Kato K , SunJ, ShahMAet al. Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The Phase III KEYNOTE-590 study. Ann. Oncol.31(Suppl. 4), S1192–S1193 (2020).
   Google Scholar
• Chau I , DokiY, AjaniJAet al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. J. Clin. Oncol.39(Suppl. 15), abstract 4000 (2021).
   Web of Science ®Google Scholar
• Lee A , KeamSJ. Tislelizumab: first approval. Drugs80(6), 617–624 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang T , SongX, XuLet al. The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions. Cancer Immunol. Immunother.67(7), 1079–1090 (2018).
   PubMed Web of Science ®Google Scholar
• Dahan R , SegaE, EngelhardtJ, SelbyM, KormanAJ, RavetchJV. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell28(3), 285–295 (2015).
   PubMed Web of Science ®Google Scholar
• Hong Y , FengY, SunHet al. Tislelizumab uniquely binds to the CC’ loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage. FEBS Open Bio11(3), 782–792 (2021).
   PubMed Web of Science ®Google Scholar
• Desai J , DevaS, LeeJSet al. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors. J. Immunother. Cancer8(1), e000453 (2020).
   PubMed Web of Science ®Google Scholar
• Shen L , GuoJ, ZhangQet al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, Phase I/II study. J. Immunother. Cancer8(1), e000437 (2020).
   PubMed Web of Science ®Google Scholar
• Xu J , BaiY, XuNet al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma. Clin. Cancer Res.26(17), 4542–4550 (2020).
   PubMed Web of Science ®Google Scholar
• Shen L , KatoK, KimS-Bet al. RATIONALE 302: randomized, Phase III study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma. J. Clin. Oncol.39(Suppl.15), 4012 (2021).
   Web of Science ®Google Scholar
• Liu SY , WuYL. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin. Investig. Drugs29(12), 1355–1364 (2020).
   PubMed Web of Science ®Google Scholar
• Oh P , DuKL, LeichmanL, AifantisI. PD-1 blockade enhances the efficacy of chemoradiation in a mouse model of esophageal cancer. Int. J. Radiat. Oncol. Biol. Phys.96(2), S127–S128 (2016).
   PubMedGoogle Scholar
• Antonia SJ , VillegasA, DanielDet al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med.377(20), 1919–1929 (2017).
   PubMed Web of Science ®Google Scholar
• Liao XY , LiuCY, HeJF, WangLS, ZhangT. Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: a novel strategy. Oncol. Lett.18(5), 5011–5021 (2019).
   PubMed Web of Science ®Google Scholar
• Kelly RJ , SmithKN, AnagnostouVet al. Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer. J. Clin. Oncol.37(Suppl.4), 142 ((2019).
   Web of Science ®Google Scholar
• Gill S , BerryS, BiagiJet al. Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Curr. Oncol.18(Suppl. 2), S5–S10 (2011).
   PubMedGoogle Scholar
• Rice TW , IshwaranH, FergusonMK, BlackstoneEH, GoldstrawP. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J. Thorac. Oncol.12(1), 36–42 (2017).
   PubMed Web of Science ®Google Scholar